Silikis 3µg/g salbe (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
37 | Generalised pustular psoriasis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-005344-83-DE (EUCTR) | 09/02/2007 | 07/11/2006 | A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98 | A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98 | Psoriasis is a common inherited autoimmune disease that affects 2-3% of the world-wide population. There are several recognized forms of psoriasis, such as plaque psoriasis, which is also known as psoriasis vulgaris and guttate, inverse, erythrodermic and pustular psoriasis, which can coexist within the same patient. The most common form is the plaque psoriasis. MedDRA version: 8.1;Level: LLT;Classification code 10037153;Term: Psoriasis | Product Name: P32/98 3% Product Code: P32/98 Trade Name: Silikis 3µg/g Salbe INN or Proposed INN: Calcitriol | Probiodrug AG | NULL | Not Recruiting | Female: yes Male: yes | Germany |